Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Glenmark Pharmaceuticals Limited — Q2 FY26
Glenmark's Q2 FY26 consolidated revenue surged 76% YoY to ₹6,047 crore, driven by the ISB 2001 out-licensing deal which contributed ₹4,466 crore in North America.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark's Q2 FY26 consolidated revenue surged 76% YoY to ₹6,047 crore, driven by the ISB 2001 out-licensing deal which contributed ₹4,466 crore in North America. Excluding this, core business grew 7.4%. India formulation sales fell 87% due to GST-driven distributor destocking, but management expects a rebound to ₹1,150-1,200 crore run-rate from Q3. The company used the $700 million upfront payment to repay all debt, becoming net cash positive. EBITDA margin is guided to 23% immediately, targeting 25%+. Key growth drivers include respiratory launches, IGI's multi-specific antibody platform (ISB 2301 entering clinics in FY27), and specialty products like Ryaltris. Risk: Legacy distribution model remains vulnerable to regulatory changes, as seen with GST disruption.
ग्लेनमार्क की दूसरी तिमाही में कुल आय 76% बढ़कर ₹6,047 करोड़ हो गई। इसकी मुख्य वजह अमेरिका में ISB 2001 दवा के लाइसेंस सौदे से मिले ₹4,466 करोड़ हैं। इस सौदे को छोड़ दें तो मूल कारोबार में 7.4% की बढ़ोतरी हुई। भारत में दवा बिक्री 87% गिर गई क्योंकि जीएसटी नियमों के कारण डीलरों ने स्टॉक कम किया। कंपनी को उम्मीद है कि तीसरी तिमाही से बिक्री ₹1,150-1,200 करोड़ प्रति तिमाही पर लौट आएगी। $700 मिलियन के अग्रिम भुगतान से कंपनी ने सारा कर्ज चुका दिया और अब उसके पास शुद्ध नकदी है। कंपनी का लक्ष्य अब 23% मुनाफा मार्जिन रखना है, जो जल्द ही 25% से अधिक हो सकता है। आगे बढ़ने के लिए सांस की दवाएं, नई एंटीबॉडी तकनीक और रायल्ट्रिस जैसे विशेष उत्पाद मदद करेंगे। लेकिन पुरानी बिक्री प्रणाली पर नियमों में बदलाव का खतरा बना रहता है, जैसा जीएसटी से हुआ।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
India distribution disruption from GST change
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India secondary sales growth
10.8%
+4.4pp YoY
Outperformed IPM growth of 6.4% in Q2 FY26 per IQVIA.
ISB 2001 upfront payment
$700M
N/A
Received in September 2025; eligible for up to $1.225B in milestones plus royalties.
Net cash position
₹2,647 crore
N/A
Post debt repayment of ₹1,300 crore; targeting zero gross debt by FY26 end.
IGI annual R&D spend
$70-75M
N/A
Self-funded for next 3 years; covers pipeline including ISB 2301 and three other programs.
What Changed vs Last Quarter
NEW
India business run-rate of ₹1,150-1,200 crore from Q3 FY26
Management expects India formulation sales to normalize to ₹1,150-1,200 crore per quarter starting Q3 FY26, with FY27 revenue exceeding ₹4,800 crore.
NEW
FY27 consolidated revenue target of ₹17,000-18,000 crore
Management guided FY27 topline between ₹17,000-18,000 crore, implying ~15% growth over FY26 estimated run-rate.
NEW
EBITDA margin of 23% immediately, targeting 25%+
Post balance sheet cleanup, EBITDA margin will trend to 23% and strengthen to over 25% in coming years.
NEW
Zero gross debt by FY26 end
Management committed to fully repay all gross debt by March 2026, maintaining a net cash positive balance sheet.
DROPPED
EBITDA margin to stabilize at 23%+ from Q3 FY26
Management guided that EBITDA margin will stabilize close to 23% plus range from Q3 onwards, excluding Q2 which will be impacted by IGI deal accounting.
DROPPED
India business to grow 10-15% CAGR over 3-5 years
Management expects India business to grow at 10-15% CAGR over the next 3-5 years, with secondary and reported growth converging from Q3.
DROPPED
Europe and emerging markets to return to double-digit growth in FY26
Europe region expected to return to double-digit growth from Q2 onwards, and emerging markets anticipated to grow double-digit on constant currency basis in FY26.
DROPPED
Monroe facility to restart commercial manufacturing this year
Management expects to restart commercial manufacturing at the Monroe facility this year, pending FDA resolution of observations.
NEW RISK
India distribution disruption from GST change
The three-tier distribution model caused a one-time 87% drop in primary sales due to inventory destocking; similar regulatory changes could recur.
NEW RISK
Recurring write-offs and litigation costs
Analyst highlighted past write-offs (Mondro, Zeta, antitrust) totaling significant amounts; management acknowledged but offered limited assurance on future controls.
NEW RISK
IGI pipeline execution risk
ISB 2301 and three other multi-specific programs are preclinical; failure to advance or partner could impair value.
NEW RISK
Geopolitical uncertainty in emerging markets
EM revenue declined 6.5% due to geopolitical issues in Latin America and West Africa; recovery uncertain.
RISK GONE
Monroe facility FDA observations unresolved
Five observations from last FDA inspection remain unresolved; management is awaiting FDA response. This could delay injectable product launches and revenue.
RISK GONE
US antitrust litigation ongoing
Glenmark USA is still defending against multiple antitrust lawsuits; settlement with direct purchaser class is subject to court approval, and other classes remain.
RISK GONE
India business drag from diabetes segment and tail brand discontinuation
Reported India growth lagged secondary sales due to discontinuation of low-margin brands and diabetes underperformance; recovery expected only from Q3.
RISK GONE
ISB 2001 deal closing delay or unfavorable terms
The AbbVie partnership is expected to close in September; any delay or renegotiation could impact cash position and IGI funding.
Fast read
Guidance and risk preview
Management expects India formulation sales to normalize to ₹1,150-1,200 crore per quarter starting Q3 FY26, with FY27 revenue exceeding ₹4,800 crore.
The three-tier distribution model caused a one-time 87% drop in primary sales due to inventory destocking; similar regulatory changes could recur.
View Risks →